{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Complete Response (CR): repeat bone marrow (BM) shows \\<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\\>110 g/L), neutrophils (≥1.0x10\\^9/L), platelets (≥100x10\\^9/L), blasts (0%) and no dysplasia. Partial Response (PR): same as CR for peripheral blood except BM shows blasts decrease by ≥ 50% but still \\> 5% or a less advanced FAB classification from pretreatment. Hematological response=CR+PR.","groups":[{"description":"Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\npharmacological study: Correlative studies","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Hematological Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}